Show simple item record

dc.contributor.authorVidal, Silvia
dc.contributor.authorPuig, Lluís
dc.contributor.authorCarrascosa-Carrillo, José-Manuel
dc.contributor.authorGonzález-Cantero, Álvaro
dc.contributor.authorRuiz-Carrascosa, José-Carlos
dc.contributor.authorVelasco-Pastor, Antonio-Manuel
dc.date.accessioned2021-11-04T11:01:35Z
dc.date.available2021-11-04T11:01:35Z
dc.date.issued2021
dc.identifier.issn1661-6596spa
dc.identifier.urihttp://hdl.handle.net/10641/2577
dc.description.abstractThe paradigm of psoriasis as a Th17-driven disease has evolved in the last years towards a much deeper knowledge of the complex pathways, mechanisms, cells, and messengers involved, highlighting the crucial role played by the IL-17 family of cytokines. All IL-17 isoforms signal through IL-17R. Five subunits of IL-17R have been described to date, which couple to form a homo- or heteroreceptor complex. Characteristically, IL-17RA is a common subunit in all hetero-receptors. IL-17RA has unique structural—containing a SEFIR/TILL domain—and functional—requiring ACT-1 for signaling—properties, enabling Th17 cells to act as a bridge between innate and adaptive immune cells. In psoriasis, IL-17RA plays a key role in pathogenesis based on: (a) IL-17A, IL-17F, and other IL-17 isoforms are involved in disease development; and (b) IL-17RA is essential for signaling of all IL-17 cytokines but IL-17D, whose receptor has not been identified to date. This article reviews current evidence on the biology and role of the IL-17 family of cytokines and receptors, with focus on IL-17RA, in psoriasis and some related comorbidities, and puts them in context with current and upcoming treatments.spa
dc.language.isoengspa
dc.publisherInternational Journal of Molecular Sciencesspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectpsoriasisspa
dc.subjectTh17spa
dc.subjectIL-17spa
dc.subjectIL-17Rspa
dc.subjectmonoclonal antibodiesspa
dc.subjectsecukinumabspa
dc.subjectixekizumabspa
dc.subjectbimekizumabspa
dc.subjectbrodalumabspa
dc.titleFrom Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment.spa
dc.typearticlespa
dc.description.versionpost-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent1.096 KBspa
dc.identifier.doi10.3390/ijms22136740spa
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/22/13/6740spa


Files in this item

FilesSizeFormatView
1.- From Messengers to Receptors ...1.069MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España